Axsome Therapeutics AXSM underwent analysis by 28 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 16 | 12 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 11 | 9 | 0 | 0 | 0 |
| 2M Ago | 5 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $165.07, a high estimate of $212.00, and a low estimate of $121.00. This upward trend is apparent, with the current average reflecting a 9.62% increase from the previous average price target of $150.59.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Axsome Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Vikram Purohit | Morgan Stanley | Raises | Overweight | $190.00 | $125.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $212.00 | $195.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $200.00 | $200.00 |
| Ami Fadia | Needham | Maintains | Buy | $153.00 | $153.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $200.00 | $190.00 |
| Joon Lee | Truist Securities | Raises | Buy | $200.00 | $190.00 |
| Leonid Timashev | RBC Capital | Raises | Outperform | $192.00 | $143.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $153.00 | $153.00 |
| Ami Fadia | Needham | Raises | Buy | $153.00 | $133.00 |
| Cerena Chen | Wells Fargo | Raises | Overweight | $160.00 | $140.00 |
| David Hoang | Deutsche Bank | Announces | Buy | $176.00 | - |
| Jason Gerberry | B of A Securities | Raises | Buy | $167.00 | $143.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $195.00 | $137.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $190.00 | $190.00 |
| Marc Goodman | Leerink Partners | Raises | Outperform | $150.00 | $110.00 |
| Ami Fadia | Needham | Maintains | Buy | $133.00 | $133.00 |
| Graig Suvannavejh | Mizuho | Raises | Outperform | $137.00 | $122.00 |
| Joon Lee | Truist Securities | Raises | Buy | $190.00 | $180.00 |
| Brian Abrahams | RBC Capital | Raises | Outperform | $143.00 | $139.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Raises | Buy | $190.00 | $180.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $139.00 | $139.00 |
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Buy | $180.00 | $180.00 |
| Ami Fadia | Needham | Maintains | Buy | $133.00 | $133.00 |
| Joon Lee | Truist Securities | Raises | Buy | $180.00 | $150.00 |
| Ami Fadia | Needham | Maintains | Buy | $133.00 | $133.00 |
| Graig Suvannavejh | Mizuho | Lowers | Outperform | $122.00 | $124.00 |
| Ami Fadia | Needham | Maintains | Buy | $130.00 | $130.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $121.00 | $121.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Axsome Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Axsome Therapeutics compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Axsome Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Axsome Therapeutics analyst ratings.
Delving into Axsome Therapeutics's Background
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Understanding the Numbers: Axsome Therapeutics's Finances
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Axsome Therapeutics displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 66.04%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Axsome Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -63.08%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Axsome Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -99.94%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Axsome Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -13.26%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.38, caution is advised due to increased financial risk.
The Significance of Analyst Ratings Explained
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
